Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTIFY: PLN-101095 Monotherapy and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT06270706Phase 1Recruiting
- Sponsor
- Pliant Therapeutics
- Start
- Aug 2023
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of PLN-101095 in solid tumor (8 arms), sponsored by Pliant Therapeutics. Primary endpoints: Safety and tolerability of PLN-101095 in combination with pembrolizumab at 35 days and Anti-tumor activity of PLN-101095 in combination with pembrolizumab. Started Aug 2023; status: recruiting.
02
Drugs
PLN-101095
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06270706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06270706.